LY2181308 (ISIS 23722; Lilly and Co., Indianapolis, IN, USA and ISIS Pharmaceuticals, Carlsbad, CA, USA) is a novel 2′-O-methoxymethyl modified second-generation ASO designed to complementarily bind to human survivin mRNA, with the aim of inhibiting its expression and restoring the physiological programmed cell death pathway in cancer cells [132]. This evidence concerns the gene BIRC5 and cancer.